{"schema_version":"secwatch.filing_event.v1","accession":"0001000228-22-000066","form_type":"8-K","ticker":"HSIC","cik":"0001000228","company_name":"HENRY SCHEIN INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.111039+00:00","generated_at":"2026-06-22T16:44:28.054604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Henry Schein reports record Q3 non-GAAP diluted EPS of $1.15; narrows FY2022 guidance","bullets":["Q3 net sales $3.1B (-3.5% YoY); internal sales ex-PPE/COVID test kits +6.8% in local currencies.","GAAP diluted EPS $1.09 vs $1.15; Non-GAAP diluted EPS $1.15 vs $1.10 (record).","Global Dental internal sales +1.2% local currency; Medical internal sales ex-PPE/COVID +9.3%.","FY2022 non-GAAP EPS guidance narrowed to $4.79-$4.87; sales growth guidance lowered to ~1.5-2.5%.","Repurchased 1.2M shares for $90.5M in Q3; $400M remaining in buyback authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001000228-22-000066","json":"https://secwatch.observer/filing/0001000228-22-000066.json","markdown":"https://secwatch.observer/filing/0001000228-22-000066.md","text":"https://secwatch.observer/filing/0001000228-22-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000228/000100022822000066/0001000228-22-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000228/000100022822000066/hsic-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T16:44:28.054604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f6b20ee01c1243f5aad7d9ce11d57f5b99c1154","claim":"HENRY SCHEIN INC reported the nine months ended September 24, 2022 results: revenue $9.3 billion, net income $491 million, EPS $3.55. Guidance reaffirmed.","evidence_excerpt":"Total net sales for the first nine months of 2022 were $9.3 billion, an increase of 2.3% compared with the first nine months of 2021. The 2.3% increase included 2.4% internal growth in local currencies excluding acquisitions and 2.1% growth from acquisitions, offset by a 2.2% decrease related to foreign currency exchange. Sales of PPE and COVID-19 test kits for the first nine months were $991 million, which is $344 million lower than in the prior-year period. When excluding sales of PPE and COVID-19 test kits, our internal sales growth for the first nine months of 2022 in local currencies was 7.3% compared with the prior-year period. ● GAAP net income for the first nine months of 2022 was $491 million, or $3.55 per diluted share, compared with GAAP net income for the first nine months of 2021 of $484 million, or $3.40 per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000228/000100022822000066/0001000228-22-000066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 24, 2022"},{"label":"Revenue","value":"$9.3 billion"},{"label":"Net income","value":"$491 million"},{"label":"EPS","value":"$3.55"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c1f0c6365045ce70e88ed8a8a36b05ebc4153c35","claim":"HENRY SCHEIN INC reported the three months ended September 24, 2022 results: revenue $3.1 billion, net income $150 million, EPS $1.09. Guidance reaffirmed.","evidence_excerpt":"Total net sales for the quarter were $3.1 billion, a decrease of 3.5% compared with the third quarter of 2021. The 3.5% decrease included a 2.4% decrease in local currencies excluding acquisitions, 1.8% growth from acquisitions and a 2.9% decrease related to foreign currency exchange 1 . Sales of PPE and COVID-19 test kits in the third quarter were $244 million, which is $260 million lower than the prior-year period. When excluding sales of PPE and COVID-19 test kits, our third-quarter internal sales growth in local currencies was 6.8% compared with the prior- year period. ● GAAP net income for the quarter was $150 million, or $1.09 per diluted share, compared with third-quarter 2021 GAAP net income of $162 million, or $1.15 per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000228/000100022822000066/0001000228-22-000066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 24, 2022"},{"label":"Revenue","value":"$3.1 billion"},{"label":"Net income","value":"$150 million"},{"label":"EPS","value":"$1.09"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}